Tuesday, October 16, 2018


   The ongoing feud between brand-name pharmaceutical companies and their generic rivals has taken an unusual turn, with Canada’s competition watchdog alleging some brand firms are trying to stymie generic companies by blocking access to their medicines.
  Health Canada requires generic-drug producers to conduct tests proving their cheaper copies act similarly in people as the original drug, meaning they need samples of the brand-name product.
   But pharmaceutical companies have “increasingly” been denying or delaying sales of their medicines to the generic manufacturers, the Competition Bureau of Canada charges in court documents obtained by the National Post.

No comments:

Post a Comment